Evidence map›Paper›PMID 30559206›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Human induced pluripotent stem cell-derived MGE cell grafting after status epilepticus attenuates chronic epilepsy and comorbidities via synaptic integration.

Dinesh Upadhya, Bharathi Hattiangady, Olagide W Castro, Bing Shuai, Maheedhar Kodali, Sahithi Attaluri, Adrian Bates, Yi Dong, Su-Chun Zhang, Darwin J Prockop and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
5.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 126 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Chemogenetics with PSAMGene therapy · 2025
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. FDA-approved cannabidiol [EpidiolexMilitary Medical Research · 2024
    Article
  18. Article
  19. Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Dinesh UpadhyaInstitute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX 76502.
Bharathi HattiangadyInstitute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX 76502.
Olagide W CastroInstitute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, College Station, TX 77845.
Bing ShuaiInstitute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX 76502.
Maheedhar KodaliInstitute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX 76502.
Sahithi AttaluriInstitute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX 76502.
Adrian BatesInstitute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX 76502.
Yi DongWaisman Center, Department of Neuroscience, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706.
Su-Chun ZhangWaisman Center, Department of Neuroscience, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706.
Darwin J ProckopInstitute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX 76502; shetty@medicine.tamhsc.edu prockop@medicine.tamhsc.edu.
Ashok K ShettyInstitute for Regenerative Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX 76502; shetty@medicine.tamhsc.edu prockop@medicine.tamhsc.edu.
Central Texas Veterans Health Care System · USTemple College · USUniversity of Wisconsin–Madison · USOlin E. Teague Veterans Medical Center · USTexas A&M Health Science Center · US

Funding

Summer Research ExperienceP50MH100031 · NIMH · UNIVERSITY OF WISCONSIN-MADISON · PI GOLDSMITH, HAROLD HILL · 2013 to 2017
$10.4M
Reconstruction and Regulation of Neural Circuitry by Human NeuronsR01NS096282 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI ZHANG, SU-CHUN · 2017 to 2021
$1.7M
Transgenic Human Stem Cell Lines and ReagentsR24NS086604 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI ZHANG, SU-CHUN · 2014 to 2017
$1.1M
Memory and Mood Enhancing Therapies for Gulf War IllnessI01BX000883 · VA · OLIN TEAGUE VETERANS CENTER · PI SHETTY, ASHOK K · 2011 to 2015
–
Combined NSC Grafting and Neurogenic Drug Therapy for Temporal Lobe EpilepsyI01BX002351 · VA · OLIN TEAGUE VETERANS CENTER · PI SHETTY, ASHOK K · 2015 to 2018
–
BLR&D Research Career Scientist AwardIK6BX003612 · VA · OLIN TEAGUE VETERANS CENTER · PI SHETTY, ASHOK K · 2017 to 2019
–
BLRD VA I01 BX000883BLRD VA I01 BX002351BLRD VA IK6 BX003612NIMH NIH HHS P50 MH100031NINDS NIH HHS R01 NS096282NINDS NIH HHS R24 NS086604
6 · The paper itself

Abstract

Medial ganglionic eminence (MGE)-like interneuron precursors derived from human induced pluripotent stem cells (hiPSCs) are ideal for developing patient-specific cell therapy in temporal lobe epilepsy (TLE). However, their efficacy for alleviating spontaneous recurrent seizures (SRS) or cognitive, memory, and mood impairments has never been tested in models of TLE. Through comprehensive video- electroencephalographic recordings and a battery of behavioral tests in a rat model, we demonstrate that grafting of hiPSC-derived MGE-like interneuron precursors into the hippocampus after status epilepticus (SE) greatly restrained SRS and alleviated cognitive, memory, and mood dysfunction in the chronic phase of TLE. Graft-derived cells survived well, extensively migrated into different subfields of the hippocampus, and differentiated into distinct subclasses of inhibitory interneurons expressing various calcium-binding proteins and neuropeptides. Moreover, grafting of hiPSC-MGE cells after SE mediated several neuroprotective and antiepileptogenic effects in the host hippocampus, as evidenced by reductions in host interneuron loss, abnormal neurogenesis, and aberrant mossy fiber sprouting in the dentate gyrus (DG). Furthermore, axons from graft-derived interneurons made synapses on the dendrites of host excitatory neurons in the DG and the CA1 subfield of the hippocampus, implying an excellent graft-host synaptic integration. Remarkably, seizure-suppressing effects of grafts were significantly reduced when the activity of graft-derived interneurons was silenced by a designer drug while using donor hiPSC-MGE cells expressing designer receptors exclusively activated by designer drugs (DREADDs). These results implied the direct involvement of graft-derived interneurons in seizure control likely through enhanced inhibitory synaptic transmission. Collectively, the results support a patient-specific MGE cell grafting approach for treating TLE.

Indexed as

AffectAnimalsBrainCA1 Region, HippocampalCognitionDentate GyrusEpilepsyEpilepsy, Temporal LobeHippocampusHumansInduced Pluripotent Stem CellsMaleRatsRats, Inbred F344SeizuresStatus Epilepticuscognition and moodEEG recordingsGABA-ergic progenitorsmedial ganglionic eminencetemporal lobe epilepsy

Identifiers

PMID30559206
PMCPMC6320542
OpenAlexW2905571427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.